Paricalcitol versus calcitriol in the treatment of secondary hyperparathyroidism

Kidney International

Volumn 63, Issue 4, 2003, Pages 1483-1490

  Sprague, Stuart M ^a   Llach, Francisco ^b   Amdahl, Michael ^b   Taccetta, Carol ^b   Batlle, Daniel ^b  

^a NORTHWESTERN UNIVERSITY   (United States)

^b NONE

Author keywords

Calcitriol; ESRD; Hemodialysis; Hypercalcemia; Hyperphosphatemia; Paricalcitol; Secondary hyperparathyroidism

Indexed keywords

ALFACALCIDOL; ALKALINE PHOSPHATASE; CALCITONIN; CALCITRIOL; DIHYDROTACHYSTEROL; PARATHYROID HORMONE; PARICALCITOL;

ADULT; AGED; ARTICLE; CALCIUM BLOOD LEVEL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG EFFECT; DRUG EFFICACY; DRUG SAFETY; FEMALE; HEMODIALYSIS; HUMAN; HYPERCALCEMIA; KIDNEY FAILURE; MAINTENANCE DRUG DOSE; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PARATHYROID HORMONE BLOOD LEVEL; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SECONDARY HYPERPARATHYROIDISM; TREATMENT OUTCOME;

EID: 0037378444     PISSN: 00852538     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1523-1755.2003.00878.x     Document Type: Article

References (34)

1. HRUSKA KA, TEITELBAUM SL: Renal osteodystrophy N Engl J Med 333:166-174, 1995
2. SHERRARD DJ, HERCZ G, PEI Y, et al: The spectrum of bone disease in end-stage renal failure - An evolving disorder. Kidney Int 43:436-442, 1993
3. SLATOPOLSKY E, DELMEZ JA: Pathogenesis of secondary hyperparathyroidism. Am J Kidney Dis 23:229-236, 1994
4. SILVER J, RUSSELL J, SHERWOOD LM: Regulation by vitamin D metabolites of messenger RNA for preproparathyroid hormone in isolated bovine parathyroid cells. Proc Natl Acad Sci USA 82:4270-4273, 1985
5. SLATOPOLSKY E, FINCH J, DENDA M, et al: Phosphorus restriction prevents parathyroid gland growth: High phosphorus directly stimulates PTH secretion in vitro. J Clin Invest 97:2534-2540, 1996
6. BROWN AJ, DUSSO A, SLATOPOLSKY E: Vitamin D. Am J Physiol 277(2 Pt 2):F157-F175, 1999
7. DELMEZ JA, TINDIRA C, GROOMS P, et al: Parathyroid hormone suppression by 1,25-dihydroxyvitamin D, a role for increased sensitivity to calcium. J Clin Invest 83:1349-1355, 1989
8. SLATOPOLSKY E, WEERTS C, THIELAN J, et al: Marked suppression of secondary hyperparathyroidism by intravenous administration of 1,25-dihydroxy-cholecalciferol in uremic patients. J Clin Invest 74:2136-2143, 1984
9. SPRAGUE SM, MOE SM: Safety and efficacy of long-term treatment of secondary hyperparathyroidism by low-dose intravenous calcitriol. Am J Kidney Dis 19:532-539, 1992
10. QUARLES LD, INDRIDASON ON: Calcitriol administration in end-stage renal disease: intravenous or oral? Pediatr Nephrol 10:331-336, 1996
11. MOE SM, KRAUS MA, GASSENSMITH CM, et al: Safety and efficacy of pulse and daily calcitriol in patients on CAPD: A randomized trial. Nephrol Dial Transplant 13:1234-1241, 1998
12. COBURN JW: Use of oral and parenteral IV calcitriol in the treatment of renal osteodystrophy. Kidney Int 38 (Suppl 29):S54-S61, 1990
13. QUARLES LD, YOHAY D, CARROL B, et al: Prospective trial of pulse oral versus intravenous calcitriol treatment of hyperparathyroidism in ESRD. Kidney Int 95:1710-1721, 1994
14. SHOYI S, NISHIZAWA Y, TABATA T, et al: Influence of serum phosphate on the efficacy of oral 1,25 hydroxyvitamin D3 pulse therapy. Miner Electrolyte Metab 22:223-238, 1995
15. DELMEZ JA, SLATOPOLSKY E: Hyperphosphatemia: its consequences and treatment in patients with chronic renal disease. Am J Kidney Dis 19:303-317, 1992
16. CANNATA AJB: Adynamic bone and chronic renal failure: an overview. Am J Med Sci 320:81-84, 2000
17. BLOCK GA, HULBERT-SHEARON TE, LEVIN NW, et al: Association of serum phosphorus and calcium x phosphorus product with mortality risk in chronic hemodialysis patients: A national study. Am J Kidney Dis 31:607-617, 1998
18. GOODMAN WG, GOLDIN J, KUIZON BD, et al: Coronary artery calcification in young adults with end stage renal disease undergoing dialysis. N Engl J Med 342:1478-1483, 2000
19. MAZHAR RA, JOHNSON RJ, GILLEN D, et al: Risk factors and mortality associated with calciphylaxis in end-stage renal disease. Kidney Int 60:324-332, 2001
20. CHERTOW GM, DILLON M, BURKE SK, et al: A randomized trial of sevelamer hydrochloride (RenaGel) with and without supplemental calcium: Strategies for the control of hyperphosphatemia and hyperparathyroidism in hemodialysis patients. Clin Nephrol 51:18-26, 1999
21. 2 (paricalcitol) safely and effectively reduces the levels of intact PTH in patients on hemodialysis. J Am Soc Nephrol 10:1427-1432, 1998
22. LLACH F, YUDD M: Paricalcitol in dialysis patients with calcitriol-resistant secondary hyperparathyroidism. Am J Kidney Dis 38 (Suppl 5):S45-S50, 2001
23. 2, suppresses parathyroid hormone secretion in uremic rats in the absence of hypercalcemia. Am J Kidney Dis 26:852-860, 1995
24. 3, suppresses serum PTH and parathyroid gland growth in uremic rats without elevation of intestinal vitamin D receptor content. Am J Kidney Dis 30:105-112, 1997
25. FINCH J, BROWN A, SLATOPOLSKY E: Differential effects of 1,25-dihydroxy-vitamin D3 and 19-nor-1,25-dihydroxy-vitamin D2 on calcium and phosphorus resorption in bone. J Am Soc Nephrol 10:980-985, 1999
26. BALINT E, MARSHALL C, SPRAGUE SM: Effect of the vitamin D analogues paricalcitol and calcitriol on bone mineral in vitro. Am J Kidney Dis 36:789-796, 2000
27. SPRAGUE SM, LERMA E, MCCORMMICK D, et al: Suppression of parathyroid hormone secretion in hemodialysis patients: Comparison of paricalcitol with calcitriol. Am J Kidney Dis 38 (Suppl 5):S51-S56, 2001
28. LLACH F, KESHAV G, GOLDBLAT MV, et al: Suppression of parathyroid hormone secretion in hemodialysis patients by a novel vitamin D analogue: 19-nor-1,25-dihydroxyvitamin D2. Am J Kidney Dis 32:48S-54S, 1998
29. BLOCK G, PORT F: Re-evaluation of risks associated with hyperphosphatemia and hyperparathyroidism in dialysis patients: Recommendations for a change in management. Am J Kidney Dis 35:1226-1237, 2000
30. FUKUDA N, TANAKA H, TOMINAGA Y, et al: Decreased 1,25-dihydroxyvitamin D3 receptor density is associated with a more severe form of parathyroid hyperplasia in chronic uremic patients. J Clin Invest 92:1436-1443, 1993
31. BLACK W, SLATOPOLSKY E, ELKAN I, et al: Parathyroid morphology in suppressible and nonsuppressible renal hyperparathyroidism. Lab Invest 23:497-509, 1970
32. MAYER G, HABENER J, POTTS J: Parathyroid hormone in vivo: Demonstration of a calcium-independent nonsuppressible component of secretion. J Clin Invest 57:678-683, 1976
33. DRUEKE TB: The pathogenesis of parathyroid gland hyperplasia in chronic renal failure. Kidney Int 48:259-272, 1995
34. TOMINAGA Y: Mechanism of parathyroid tumorigenesis in uraemia. Nephrol Dial Transplant 14(Suppl):63-65, 1999